

February 2, 2022

**Quarterly Financial Summary**  
**(For the first nine months of the fiscal year ending March 31, 2022)**  
**[Under Japanese GAAP]**  
**(Consolidated)**

**Listed Company:** Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)  
Code Number: 4559 (URL: <https://www.zeria.co.jp/>)  
Representative: Mitsuhiro Ibe, Representative Director, President & COO  
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039  
Scheduled date to submit the Quarterly Securities Report: February 4, 2022  
Scheduled date to commence dividend payments: –  
Preparation of supplementary documents to the quarterly financial results: None  
Holding of quarterly financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2021 through December 31, 2021)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2021	45,104	11.7	5,495	41.6	5,613	57.6	4,043	9.2
December 31, 2020	40,370	–	3,879	–	3,561	–	3,702	–

Note: Comprehensive income: For the nine months ended December 31, 2021: 2,169 million yen [(45.8)%]

For the nine months ended December 31, 2020: 4,001 million yen [–%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
December 31, 2021	89.33	–
December 31, 2020	80.18	–

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure for the nine months ended December 31, 2020, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. Consequently, the percentage of year-on-year change of each figure for the nine months ended December 31, 2020, is not shown.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
December 31, 2021	125,981	55,496	43.9	1,228.23
March 31, 2021	121,860	56,152	45.9	1,225.09

Reference: Equity: As of December 31, 2021: 55,313 million yen As of March 31, 2021: 55,985 million yen

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure as of March 31, 2021, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations.

## 2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
Year ended March 31, 2021	Yen –	Yen 17.00	Yen –	Yen 17.00	Yen 34.00
Year ending March 31, 2022	–	17.00	–		
Year ending March 31, 2022 (Forecast)				17.00	34.00

Note: Revision of the forecast of dividends most recently announced: None

## 3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)

(Percentage figures indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	60,000	13.7	5,300	52.5	5,200	62.1	3,700	17.7	81.84

Note: Revision of the financial forecast most recently announced: None

Year-on-year changes are presented in comparison with figures from the previous fiscal year after retrospective adjustments as retrospective adjustments were carried out due to changes in accounting policies.

### \* Notes

(1) Significant changes of subsidiaries during the nine months ended December 31, 2021 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the period (including treasury shares):

As of December 31, 2021: 53,119,190 shares As of March 31, 2021: 53,119,190 shares

2) Number of treasury shares as of the end of the period:

As of December 31, 2021: 8,084,330 shares As of March 31, 2021: 7,420,461 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the nine months ended December 31, 2021: 45,266,623 shares

For the nine months ended December 31, 2020: 46,174,949 shares

\* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.

\* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.